The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127. DOI:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007;31(11):1461–1468.
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009;39(7):548–553.
   PubMed Web of Science ®Google Scholar
• Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012;36:1–5.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Ruf L, Bernhardt A, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol. 2010;21:2267–2271.
   PubMed Web of Science ®Google Scholar
• Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355–2361.
   PubMed Web of Science ®Google Scholar
• Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016;113:317–322.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematol Am Soc Hematol Educ Program. 2015;2015:299–307.
   PubMedGoogle Scholar
• Glenthøj A, Ørskov AD, Hansen JW, et al. Immune mechanisms in myelodysplastic syndrome. Int J Mol Sci. 2016;17(6). DOI:10.3390/ijms17060944.
   PubMed Web of Science ®Google Scholar
• Anderson L, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100:822–828.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016;55:291–300.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016;91(5):E280–3. DOI:10.1002/ajh.24333
   PubMed Web of Science ®Google Scholar
• Wilson AB, Neogi T, Prout M, et al. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the general practice research database. Cancer Epidemiol. 2014;38:544–549.
   PubMed Web of Science ®Google Scholar
• Giannouli S, Kanellopoulou T, Voulgarelis M. Myelodysplasia and autoimmunity. Curr Opin Rheumatol. 2012;24:97–102.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaninoni A, Imperiali FG, et al. Anti-erythroblast autoimmunity in early myelodysplastic syndromes. Haematologica. 2007;92:19–26.
   PubMed Web of Science ®Google Scholar
• Zaninoni A, Imperiali FG, Cattaneo A, et al. Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes. Transfusion. 2016;56:2037–2041.
   PubMed Web of Science ®Google Scholar
• Schneider RK, Schenone M, Ferreira MV, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22:288–297.
   PubMed Web of Science ®Google Scholar
• Kook H, Zeng W, Guibin C, et al. Increased cytotoxic T cells with effector phenotype in aplastic anemia an myelodysplasia. Exp Hematol. 2001;29:1270–1277.
   PubMed Web of Science ®Google Scholar
• Epperson DE, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res. 2001;25:1075–1083.
   PubMed Web of Science ®Google Scholar
• Matsutani T, Yoshioka T, Tsuruta Y, et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res. 2003;27:305–312.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Afzali B, Lim Z, et al. IL-17 producing CD4+ T cells, proinflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145:64–72.
   PubMed Web of Science ®Google Scholar
• Boula A, Voulgarelis M, Giannouli S, et al. Effect of cA2 antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12:3099–3108.
   PubMed Web of Science ®Google Scholar
• Lazarini M, Traina F, Winnischofer SM, et al. Effects of thalidomide on longterm bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers. Leuk Res. 2011;35:1102–1107.
   PubMed Web of Science ®Google Scholar
• Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112:3434–3443.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Ingram W, Hayden J, et al. CD4+/CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110:847–850.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. Philadelphia, PA: Saunders Ed; 2012.
   Google Scholar
• Barcellini W, Clerici G, Montesano R, et al. In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol. 2000;111:452–460.
   PubMed Web of Science ®Google Scholar
• Toriani-Terenzi C, Fagiolo E. IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia. Ann N Y Acad Sci. 2005;1051:29–44.
   PubMed Web of Science ®Google Scholar
• Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol. 2011;21:297–304.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang T, Liu Z, et al. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol. 2012;40:994–1004.
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4–13.
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–1124.
   PubMed Web of Science ®Google Scholar
• Ogawara H, Handa H, Morita K, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;71:283–288.
   PubMed Web of Science ®Google Scholar
• Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:1325–1328.
   PubMed Web of Science ®Google Scholar
• Rocha AM, Souza C, Rocha GA, et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica. 2011;96:1560–1564.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang L, Xia R, et al. Plasma levels of interleukin 12 family cytokines and their relevant cytokines in adult patients with chronic immune thrombocytopenia before and after high-dose dexamethasone treatment. Med Princ Pract. 2015;24:458–464.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood. 1999;93:1951–1958.
   PubMed Web of Science ®Google Scholar
• Zermati Y, Fichelson S, Valensi F, et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. 2000;28:885–894.
   PubMed Web of Science ®Google Scholar
• Akel S, Petrow-Sadowski C, Laughlin MJ, et al. Neutralization of autocrine transforming growth factor-beta in human cord blood CD34(+)CD38(-)Lin(-) cells promotes stem-cell-factor-mediated erythropoietin-independent early erythroid progenitor development and reduces terminal differentiation. Stem Cells. 2003;21:557–567.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bai H, Liu Y, et al. Cooperative effect of erythropoietin and TGF-β inhibition on erythroid development in human pluripotent stem cells. J Cell Biochem. 2015;116:2735–2743.
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Stamatopoulos K, Damianaki A, et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. Br J Haematol. 2005;128:863–876.
   PubMed Web of Science ®Google Scholar
• Stavroulaki E, Kastrinaki MC, Pontikoglou C, et al. Mesenchymal stem cells contribute to the abnormal bone marrow microenvironment in patients with chronic idiopathic neutropenia by overproduction of transforming growth factor-β1. Stem Cells Dev. 2011;20:1309–1318.
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Palmblad J, Eliopoulos GD. Non-immune chronic idiopathic neutropenia of adult: an overview. Eur J Haematol. 2001;67:35–44.
   PubMed Web of Science ®Google Scholar
• Spanoudakis M, Koutala H, Ximeri M, et al. T-cell receptor Vβ repertoire analysis in patients with chronic idiopathic neutropenia demonstrates the presence of aberrant T-cell expansions. Clin Immunol. 2010;137:384–395.
   PubMed Web of Science ®Google Scholar
• Pavlaki KI, Kastrinaki MC, Klontzas M, et al. Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia. Haematologica. 2012;97:743–750.
   PubMed Web of Science ®Google Scholar
• Velegraki M, Koutala H, Tsatsanis C, et al. Increased levels of the high mobility group box 1 protein sustain the inflammatory bone marrow microenvironment in patients with chronic idiopathic neutropenia via activation of toll-like receptor 4. J Clin Immunol. 2012;32:312–322.
   PubMed Web of Science ®Google Scholar
• Giannouli S, Tzoanopoulos D, Ritis K, et al. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor- 1 (IRF-1) expression. Ann Rheum Dis. 2004;63:578–582.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373:35–47.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698–2704.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–2498.
   PubMed Web of Science ®Google Scholar
• Saito C, Ishiyama K, Yamazaki H, et al. Hypomegakaryocytic thrombocytopenia (HMT): an immune-mediated bone marrow failure characterized by an increased number of PNH-phenotype cells and high plasma thrombopoietin levels. Br J Haematol. 2016;175:246–251.
   PubMed Web of Science ®Google Scholar
• Damianaki A, Stagakis E, Mavroudi I, et al. Minor populations of paroxysmal nocturnal haemoglobinuria type cells in patients with chronic idiopathic neutropenia. Eur J Haematol. 2016 Apr 28. DOI:10.1111/ejh.12766.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100:1570–1574.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21:1436–1441.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005;106:841–851.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26:2505–2511.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Mailloux AW, Chen DT, et al. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014;99:1176–1183.
   PubMed Web of Science ®Google Scholar
• Jonásova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304–309.
   PubMed Web of Science ®Google Scholar
• Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res. 2003;27:783–788.
   PubMed Web of Science ®Google Scholar
• Parikh AR, Olnes MJ, Barrett AJ. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol. 2012;49:304–311.
   PubMed Web of Science ®Google Scholar
• Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006;91:667–670.
   PubMed Web of Science ®Google Scholar
• Remacha AF, Arrizabalaga B, Bueno J, et al. Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment. Haematologica. 2010;95:339–340.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28:5166–5173.
   PubMed Web of Science ®Google Scholar
• Barcellini W. Current treatment strategies in autoimmune hemolytic disorders. Expert Rev Hematol. 2015;8:681–691.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Consonni D, et al. Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study. Eur J Intern Med. 2015;26:611–615.
   PubMed Web of Science ®Google Scholar
• Hohensinner PJ, Goronzy JJ, Weyand CM. Telomere dysfunction. Autoimmun Aging Aging Dis. 2011;2:524–537.
   PubMed Web of Science ®Google Scholar
• Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. N Engl J Med. 2016;374:1922–1931.
   PubMed Web of Science ®Google Scholar
• Hwang SM, Kim SY, Kim JA, et al. Short telomere length and its correlation with gene mutations in myelodysplastic syndrome. J Hematol Oncol. 2016;9:62.
   PubMed Web of Science ®Google Scholar
• Duffy L, O’Reilly SC. Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments. Immunotargets Ther. 2016;5:69–80. DOI:10.2147/ITT.S89795.
   PubMed Web of Science ®Google Scholar
• Varney ME, Melgar K, Niederkorn M, et al. Deconstructing innate immune signaling in myelodysplastic syndromes. Exp Hematol. 2015;43:587–598.
   PubMed Web of Science ®Google Scholar
• Wei Y, Dimicoli S, Bueso-Ramos C, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27:1832–1840.
   PubMed Web of Science ®Google Scholar
• Zaninoni A, Imperiali FG, Pomati M, et al. Bone marrow mitogen-stimulated direct antiglobulin test in a case of erythroblastic synartesis. Clin Lab. 2010;56:459–462.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. Am J Hematol. 2017;92(3):E26–E29. DOI:10.1002/ajh.24618.
   PubMed Web of Science ®Google Scholar